Education
About Us
Working with TipRanks
Follow Us
Bayer AG (BAYRY)
OTHER OTC:BAYRY
BAYRY Stock Chart & Stats
$10.94
-$0.08(-1.46%)
At close: 4:00 PM EST
$10.94
-$0.08(-1.46%)
Day’s Range― - ―
52-Week Range$5.37 - $14.56
Previous CloseN/A
Volume306.92K
Average Volume (3M)312.21K
Market Cap
$43.12B
Enterprise Value$66.52B
Total Cash (Recent Filing)$7.85B
Total Debt (Recent Filing)$37.43B
Price to Earnings (P/E)―
Beta0.57
Next Earnings
May 12, 2026EPS Estimate
0.68Next Dividend Ex-DateN/A
Dividend Yield0.29%
Share Statistics
EPS (TTM)0.18
Shares Outstanding3,929,696,000
10 Day Avg. Volume89,747
30 Day Avg. Volume312,210
Financial Highlights & Ratios
PEG Ratio-0.29
Price to Book (P/B)1.40
Price to Sales (P/S)0.83
P/FCF Ratio18.08
Enterprise Value/Market Cap1.54
Enterprise Value/Revenue1.46
Enterprise Value/Gross Profit2.49
Enterprise Value/Ebitda10.32
Forecast
1Y Price Target
$12.35Price Target Upside12.89% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)1.37
Revenue Forecast (FY)$53.82B
Bulls Say, Bears Say
Bulls Say
Diversified Business ModelBayer's presence across pharmaceuticals, consumer health, crop science and animal health reduces reliance on any single market cycle. This multi‑stream model supports steadier revenues, cross‑segment R&D synergies and risk diversification that can sustain performance over the next 2–6 months.
Clinical & Regulatory Momentum In PharmaA successful Phase III (OCEANIC‑STROKE) showing a 26% stroke reduction and Fast Track status is a structural win: it strengthens Bayer's late‑stage pipeline, accelerates regulatory timelines, and improves future commercial prospects and sustainable revenue growth beyond short‑term cycles.
Operational Efficiency (DSO) And Productivity GainsConcrete DSO savings (€700m in 2025; €2bn target) and organizational flattening are durable operational improvements. Lower structural costs and faster time‑to‑market raise sustainable margins and cash conversion, supporting long‑term competitiveness and funding capacity.
Bears Say
Multi‑year Revenue Decline And Net LossesThree straight years of falling revenue coupled with recurring net losses signals weakening core demand or portfolio challenges. Persistently negative profitability undermines return on invested capital, constrains reinvestment and raises execution risk for turning sales and margins around within the medium term.
Weakening Cash GenerationA sharp decline in operating cash flow and free cash flow reduces internal funding for R&D, capex and strategic initiatives. If this downtrend continues, it will materially limit financial flexibility and increase dependence on external financing during the next 2–6 months and beyond.
Large Litigation Liabilities And Payout RiskSubstantial litigation provisions (≈€11.8bn) and announced multi‑year payouts drive expected negative 2026 free cash flow and higher net debt. This structural legal burden will constrain capital allocation, raise refinancing and rating risk, and pressure balance‑sheet durability over the medium term.
Bayer News
BAYRY FAQ
What was Bayer AG’s price range in the past 12 months?
Bayer AG lowest stock price was $5.37 and its highest was $14.56 in the past 12 months.
What is Bayer AG’s market cap?
Bayer AG’s market cap is $43.12B.
When is Bayer AG’s upcoming earnings report date?
Bayer AG’s upcoming earnings report date is May 12, 2026 which is in 66 days.
How were Bayer AG’s earnings last quarter?
Bayer AG released its earnings results on Mar 04, 2026. The company reported $0.18 earnings per share for the quarter, beating the consensus estimate of $0.114 by $0.066.
Is Bayer AG overvalued?
According to Wall Street analysts Bayer AG’s price is currently Undervalued.
Does Bayer AG pay dividends?
Bayer AG pays a Annually dividend of $0.031 which represents an annual dividend yield of 0.29%. See more information on Bayer AG dividends here
What is Bayer AG’s EPS estimate?
Bayer AG’s EPS estimate is 0.68.
How many shares outstanding does Bayer AG have?
Bayer AG has 3,929,696,000 shares outstanding.
What happened to Bayer AG’s price movement after its last earnings report?
Bayer AG reported an EPS of $0.18 in its last earnings report, beating expectations of $0.114. Following the earnings report the stock price went down -1.822%.
Which hedge fund is a major shareholder of Bayer AG?
Currently, no hedge funds are holding shares in BAYRY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Bayer Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$12.35 (12.89% Upside)
$12.35 (12.89% Upside)
Blogger Sentiment
Bullish
BAYRY Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 33.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 2.8%
Last 30 Days ▼ 2.6%
Last 30 Days ▼ 2.6%
News Sentiment
Very Bullish
Bullish news 93%
Bearish news 7%
Bearish news 7%
Technicals
SMA
Positive
20 days / 200 days
Momentum
66.56%
12-Months-Change
Fundamentals
Return on Equity
-13.72%
Trailing 12-Months
Asset Growth
6.50%
Trailing 12-Months
Company Description
Bayer AG
Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines, medical products, medicated skincare products, nutritional supplements, and self-care solutions in dermatology, nutritional supplements, pain and cardiovascular risk prevention, digestive health, allergy, and cold and cough. The Crop Science segment offers chemical and biological crop protection products, improved plant traits, seeds, digital solution, and pest and weed control products, as well as customer service for agriculture. This segment also provides breeding, propagation, and production/processing of seeds, including seed dressing. The company has a collaboration agreement with MD Anderson Cancer Center to develop oncology drugs; research and license agreement with Dewpoint Therapeutics, Inc. for the development of new treatments for cardiovascular and gynecological diseases; collaboration agreement with Exscientia Ltd, Foundation Medicine Inc., and Evotec AG; research collaboration with Arvinas Inc.; strategic research partnership with University of Oxford to develop novel gynecological therapies; and Kyoto University to identify new drugs candidates for the treatment of pulmonary diseases. It distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. Bayer Aktiengesellschaft was founded in 1863 and is headquartered in Leverkusen, Germany.
BAYRY Company Deck
BAYRY Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call balanced clear operational progress—delivery of raised guidance, improved launch momentum in Pharma, meaningful DSO-driven cost savings, and a reduced net financial debt position in 2025—against substantial legal and cashflow headwinds. Management articulated tangible growth drivers across Crop Science, Pharma and Consumer Health and concrete cost-savings milestones, but also disclosed large litigation provisions (EUR 11.8 billion liabilities), expected negative free cash flow in 2026 due to ~EUR 5 billion litigation-related payouts, projected net debt increase and significant product declines (notably Xarelto and Eylea). Given the mix of strong operational execution and material financial/legal risks that will weigh on near-term cash flow and balance-sheet metrics, the tone of the call is cautiously constructive but realistic about the challenges ahead.View all BAYRY earnings summariesBAYRY Stock 12 Month Forecast
Average Price Target
$12.35
▲(12.89% Upside)
Technical Analysis
Ownership Overview
―
Insiders
0.17% Mutual Funds
0.17% Other Institutional Investors
99.44% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---